Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safusidenib in IDH1-Mutant Glioma Progressing on Vorasidenib
NCT07703436Phase 2Recruiting
- Sponsor
- Nuvation Bio
- Start
- Mar 2027
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 2 trial of safusidenib in glioma, sponsored by Nuvation Bio. Planned start Mar 2027; status: recruiting.
02
Drugs
safusidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07703436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703436.